In the Spotlight...

Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine

Investigating why patients with frameshifting CALRMUT myeloproliferative neoplasms (MPNs) with many predicted immunogenic peptides rarely show signs of CALRMUT-specific T cell responses, Gigoux et al....

Superkine IL2 and IL33 armored CAR T cells reshape the tumor microenvironment and reduce growth of multiple solid tumors

TA99 (TRP1-specific) CAR T cells expressing a high-affinity (βγ-directed) IL-2 superkine (Super2) and IL-33 delayed growth of B16F10 melanoma tumors more effectively than control TA99 cells, independe...

A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity

Kim et al. showed that rhIL-7-hyFc, a long-acting, genetically modified human IL-7 (a pro-lymphoid growth factor) fused to an IgD/G4Fc, expanded functional human CD19-CAR T cells in vitro. rhIL-7-hyFc...

Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia

A lack of tumor-specific antigens has slowed targeted cell therapy development for AML. To address this, Dong et al. engineered cytokine-induced memory-like NK (CIML NK) cells to express a TCR-like CA...

Previous Digests

Thymus cells take on various shapes to select T cells

June 22, 2022

The epithelium of the thymus plays a crucial role in T cell maturation, providing positive selection for MHC recognition by cortical thymic epithelial cells and negative selection for self-antigens by medullary thymic epithelial cells (mTECs) and antigen-presenting cells. mTECs...

Identifying biomarkers for chemo-immunotherapy outcomes in PDAC

June 15, 2022

Pancreatic ductal adenocarcinoma (PDAC) responds notoriously poorly to treatment, including immune checkpoint blockade; combination chemotherapies are the standard of care, but clinical responses remain deficient. Recently, studies in murine PDAC models improved treatment efficacy by combining chemotherapy with a...

New vaccine attracts T and NK cells to uninviting tumors

June 8, 2022

Since most cancer vaccines target antigens presented by MHC, the efficacy of such vaccines can be significantly impacted by the downregulation of antigen processing and presentation by tumor cells, which is a common feature in many cancer types. To...

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ed Fritsch

Ed Fritsch

Ute Burkhardt

Ute Burkhardt

Lauren Hitchings

Lauren Hitchings

Gaelle Lespinasse-Llambi

Gaelle Lespinasse-Llambi

Maartje Wouters

Maartje Wouters

Alex Najibi

Alex Najibi

Katherine J. Turner

Katherine J. Turner

Stan Wolf

Stan Wolf

Samuel (Sandy) Goldman

Samuel (Sandy) Goldman

Paula Hochman

Paula Hochman

Shishir Pant

Shishir Pant

Elaine Yee Lin Chung

Elaine Yee Lin Chung

Nathan Suek

Nathan Suek

Margot O'Toole

Margot O'Toole

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.